Evidence map›Paper›PMID 33738703›Full record

Trial reportInternational journal of hematology2021

Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.

Tomohiro Morio, Kenji Gotoh, Tomoyuki Imagawa, Kimio Morita, Hidenori Ohnishi, Kozo Yasui, Jutta Hofmann, John Philip Lawo, Amgad Shebl, Mikhail A Rojavin

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomohiro MorioDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan. tmorio.ped@tmd.ac.jp.ORCID http://orcid.org/0000-0002-9259-1025
Kenji GotohDepartment of Pediatrics, Kurume University Hospital, Fukuoka, Japan.
Tomoyuki ImagawaDepartment of Infectious Disease and Immunology, Kanagawa Children's Medical Center, Yokohama, Japan.
Kimio MoritaDepartment of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Hidenori OhnishiDepartment of Pediatrics, Gifu University Hospital, Gifu, Japan.
Kozo YasuiDepartment of Pediatrics, Hiroshima-City Hospital, Hiroshima, Japan.
Jutta HofmannCSL Behring AG, Bern, Switzerland.
John Philip LawoCSL Behring GmbH, Marburg, Germany.
Amgad SheblCSL Behring GmbH, Marburg, Germany.
Mikhail A RojavinCSL Behring LLC, King of Prussia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies investigating the safety of IgPro10 (Privigen

Indexed as

RegistriesAdolescentAdultAsian PeopleFemaleHumansImmunoglobulin GJapanMaleMiddle AgedPrimary Immunodeficiency DiseasesProspective StudiesImmunoglobulin GIgPro10JapanPrimary immunodeficiencySafetyTolerability

Identifiers

PMID33738703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.